Over-the-counter orlistat: Early experiences, views and attitudes of community pharmacists in Great Britain

International Journal of Clinical Pharmacy

Volumn 33, Issue 4, 2011, Pages 627-633

  Weidmann, Anita Elaine ^a   Cunningham, Scott ^a   Gray, Gwen ^a   Hansford, Denise ^a   McLay, James ^b   Broom, John ^a   Stewart, Derek ^a  

^a ROBERT GORDON UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Community pharmacist; Great Britain; Obesity; Orlistat; OTC; Over the counter medicines; Pharmacist experience; Pharmacist views

Indexed keywords

NON PRESCRIPTION DRUG; TETRAHYDROLIPSTATIN;

ADULT; CONTROLLED STUDY; DRUG COST; DRUG MISUSE; DRUG RESEARCH; FEMALE; HEALTH CARE DELIVERY; HEALTH CARE PERSONNEL; HEALTH CARE SURVEY; HUMAN; MALE; OUTCOME ASSESSMENT; PHARMACIST ATTITUDE; PRIORITY JOURNAL; QUESTIONNAIRE; REVIEW; UNITED KINGDOM;

ADULT; ATTITUDE OF HEALTH PERSONNEL; COMMUNITY PHARMACY SERVICES; FEMALE; GREAT BRITAIN; HUMANS; LACTONES; LIPASE; MALE; MIDDLE AGED; NONPRESCRIPTION DRUGS; PATIENT EDUCATION AS TOPIC; PHARMACISTS; PILOT PROJECTS; PROFESSIONAL ROLE; QUESTIONNAIRES; WEIGHT REDUCTION PROGRAMS;

EID: 80052400883     PISSN: 22107703     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11096-011-9516-z     Document Type: Review

References (32)

1. X Pi-Sunyer 2009 The medical risk of obesity Postgrad Med 121 6 21 33 19940414 10.3810/pgm.2009.11.2074
2. Ono Y, Guthold R, Strong K. World Health Organisation. 2010. WHO global comparable estimates. Available at: http://www.who.int/mediacentre/factsheets/ fs311/en/index.html. Accessed Apr 2011.
3. World Health Organization Ministerial conference on counteracting obesity. European Charter on counteracting obesity. EUR/06/5062700/8. Istanbul, Copenhagen: WHO Regional Office for Europe; 16 Nov 2006. Available at: http://www.euro.who.int/en/what-we-do/health-topics/diseases-and-conditions/ obesity/publications/pre-2009/european-charter-on-counteracting-obesity. Accessed Apr 2011.
4. EMEA European Medicines Agency: European Medicines Agency recommends first switch from prescription only to non-prescription for a centrally authorised medicine. Doc. Ref. EMEA/CHMP/493770/2008 2008. London; 23 Oct 2008. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/Press- release/2009/11/WC500014828.pdf. Accessed Apr 2011.
5. EMEA, European Medicines Agency recommends suspension of the marketing authorisation of Acomplia. Doc. Ref. EMEA/CHMP/537777/2008, 2008. London; 23 Oct 2008. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/Press- release/2009/11/WC500014774.pdf. Accessed Apr 2011.
6. EMEA, European Medicines Agency recommends suspension of the marketing authorisation of Sibutramine, EMA/39408/2010; 21 Jan 2010. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/Press-release/2010/01/ WC500069995.pdf. Accessed Apr 2011.
7. JW Anderson 2007 Orlistat for the management of overweight individuals and obesity: a review of potential for 60-mg, over-the-counter dosage Expert Opin Pharmacother 8 11 1733 1742 17685889 10.1517/14656566.8.11.1733 1:CAS:528:DC%2BD2sXoslagt74%3D (Pubitemid 47288178)
8. Royal Pharmaceutical Society of Great Britain: Practice guidance: OTC Orlistat. 2009. Available at: http://www.rpharms.com/support-pdfs/ otcorlistatguid.pdf. Accessed Apr 2011.
9. TD Filippatos CS Derdemezis IF Gazi ES Nakou D Mikhailidis MS Elisaf 2008 Orlistat-associated adverse effects and drug interactions. A critical review Drug Saf 31 1 53 65 18095746 10.2165/00002018-200831010-00005 1:CAS:528:DC%2BD1cXisFCit7Y%3D
10. J Hauptman C Lucas MN Boldrin H Collins K Segal 2000 Orlistat in the long-term treatment of obesity in the primary care setting Arch Fam Med 9 160 167 10693734 10.1001/archfami.9.2.160 1:STN:280:DC%2BD3c7lsFCjsw%3D%3D
11. S Rossner L Sjorstrom R Noack E Meinders G Noseda 2000 Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity Obes Res 8 49 61 10678259 10.1038/oby.2000.8 1:CAS:528:DC%2BD3cXpvF2msQ%3D%3D
12. MH Davidson J Hauptman M DiGiorolamo JP Foreyt CH Halsted D Heber, et al. 1999 Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial JAMA 281 235 242 9918478 10.1001/jama.281.3.235 1:CAS:528:DyaK1MXhtFSqtr8%3D (Pubitemid 29058112)
13. SM Schwartz VP Bansal C Hael M Rossi JP Engle 2008 Compliance, behaviour change and weight loss with orlistat in an over-the-counter setting Obesity 16 3 623 629 18239553 10.1038/oby.2007.96 1:CAS:528:DC%2BD1cXivVOquro%3D (Pubitemid 351328013)
14. Anon: Over-the counter medicines: in whose best interest? Lancet 2009;373(9661):354
15. G Williams 2007 Orlistat over the counter. Has a minimal effect on obesity and is no substitute for a healthy lifestyle BMJ 335 1163 1164 18006967 10.1136/bmj.39385.347049.80 (Pubitemid 350273287)
16. PJ Edwards I Roberts MJ Clarke C Diguiseppi R Wentz I Kwan R Cooper LM Felix S Pratap 2009 Methods to increase response to postal and electronic questionnaires Cochrane Database Syst Rev 8 3 MR000008
17. NICE Clinical Guideline 43: Obesity-guidance on the prevention, identification, assessment and management of overweight and obesity in adults and children. National Institute for Health and Clinical Excellence: London; 2006. pp. 1-84. Available at: http://www.nice.org.uk/nicemedia/pdf/ CG43NICEGuideline.pdf. Accessed Apr 2011.
18. E McColl A Jacoby L Thomas J Soutter C Bamford N Steen R Thomas E Harvey A Garratt J Bond 2001 Design and use of questionnaires: a review of best practice applicable to surveys of health service staff and patients Health Technol Assess 5 31 1 256 11809125 1:STN:280:DC%2BD38%2Fot1Wrsw%3D%3D
19. HF Hsieh SE Shannon 2005 Three approaches to qualitative content analysis Qual Health Res 15 9 1277 1288 16204405 10.1177/1049732305276687 (Pubitemid 41645161)
20. TA Wadden RI Berkowitz LG Womble DB Sarwer S Phelan, et al. 2005 Randomized trial of lifestyle modification and pharmacotherapy for obesity N Engl J Med 353 20 2111 2120 16291981 10.1056/NEJMoa050156 1:CAS:528: DC%2BD2MXht1ajsb%2FJ (Pubitemid 41653103)
21. A Feigenbaum S Pasternak E Zusk M Arid S Vinker 2005 Influence of intense multidisciplinary follow-up and orlistat on weight reduction in a primary care setting BMC Farm Pract 6 1 5 10.1186/1471-2296-6-5 (Pubitemid 40300806)
22. M Tinelli C Bond A Blenkinsopp M Jaffray M Watson P Hannaford 2007 Community Pharmacy Medicines Management Evaluation Team. Patient evaluation of a community pharmacy medications management service Ann Pharmacother 41 12 1962 1970 17971403 10.1345/aph.1K242 (Pubitemid 350230563)
23. J Krska C Lovelady D Connolly S Parmar MJ Davies 2010 Community pharmacy contribution to weight management: identifying opportunities Int J Pharm Pract 18 1 7 12 20405590 10.1211/ijpp.18.01.0003
24. SDI Toubro I Hermansen H Herborg A Astrup 1999 Dietary guidelines on obesity at Danish pharmacies. Results of a 12-week course with a 1-year follow up Ugeskr Laeger 161 5308 5513 10536516 1:STN:280:DC%2BD3c%2Fgs1GrtQ%3D%3D
25. ISI Um C Armour I Krass T Gill BB Chaar 2010 Managing obesity in pharmacy: the Australian experience Pharm World Sci 32 720 771 10.1007/s11096-010-9426-5
26. JP Cohen C Paquette CP Cairns 2005 Switching prescription drugs to over the counter BMJ 330 39 41 15626806 10.1136/bmj.330.7481.39 (Pubitemid 40070479)
27. D Stewart D John S Cunningham D McCaig D Hansford 2007 A comparison of community pharmacists' views of over-the-counter omeprazole and simvastatin Pharmacoepidemiol Drug Saf 16 1290 1297 17918161 10.1002/pds.1481 (Pubitemid 350303441)
28. D Hansford S Cunningham D John D McCaig D Stewart 2007 Community pharmacists' views, attitudes and early experiences of over-the-counter simvastatin Pharm World Sci 29 4 380 385 17357811 10.1007/s11096-007-9084-4 (Pubitemid 47201831)
29. A Hagler Robinson 2009 Orlistat misuse as purging in a patient with binge-easing disorder Psychosomatics 50 2 177 178 19377029 10.1176/appi.psy.50. 2.177
30. S Malhotra SL McElroy 2002 Orlistat misuse in bulimia nervosa Am J Psychiatry 159 3 492 11870021 10.1176/appi.ajp.159.3.492-a
31. S Nelson KO Hwang EV Bernstam 2009 Comparing clinician knowledge and online information regarding Alli (Orlistat) Int J Med Inform 78 772 777 19716762 10.1016/j.ijmedinf.2009.07.003
32. E Seston K Hassell 2010 Workforce update-joiners, leavers, and practising and non-practising pharmacists on the 2009 register Pharm J 284 80 82